Print

Galectin Therapeutics Announces Publication of Galectin Symposium Proceedings by the American Chemical Society  
1/28/2013 10:17:46 AM

NORCROSS, Ga.--(BUSINESS WIRE)--Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the American Chemical Society (ACS), as part of its ACS Symposium Series, has published online the proceedings from the galectin-focused symposium hosted by Galectin Therapeutics, Galectins and Disease Implications for Targeted Therapeutics. The book is edited by Dr. Anatole Klyosov, Chief Scientist at Galectin, and Dr. Peter G. Traber, Chief Executive Officer and Chief Medical Officer of Galectin.
//-->